ResearcherMedical University of South CarolinaNo recent work listed
David J. Cole
Matched on ORCID iD 0000-0003-3162-701X; OpenAlex author ID A5011910232; NIH RePORTER profile ID 1894642. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 0, last author 2)
- Trials
- 0
- Grants
- 1
- Labs led
- 1
- Collaborators
- 11
2011: 1 grant · 2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper
Papers 5
- Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. Last author DOI 10.1186/s13045-017-0459-2↗
- The CaSm (LSm1) oncogene promotes transformation, chemoresistance and metastasis of pancreatic cancer cells. Last author DOI 10.1038/oncsis.2015.45↗
- Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectab… Co-author DOI 10.1016/j.ijrobp.2013.12.030↗
- Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Co-author DOI 10.1038/cgt.2013.9↗
- Novel immunocompetent murine models representing advanced local and metastatic pancreatic cancer. Co-author DOI 10.1016/j.jss.2011.10.025↗
Grants 1
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ernest Ramsay Camp · 4 shared papers, 2012–2016 · strength 0.18
- Paper The CaSm (LSm1) oncogene promotes transformation, chemoresistance and metastasis of pancreatic cancer cells. DOI 10.1038/oncsis.2015.45↗
- Paper Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiat… DOI 10.1016/j.ijrobp.2013.12.030↗
- Paper Novel immunocompetent murine models representing advanced local and metastatic pancreatic cancer. DOI 10.1016/j.jss.2011.10.025↗
- Elizabeth C. Little · 3 shared papers, 2012–2016 · strength 0.14
- Paper The CaSm (LSm1) oncogene promotes transformation, chemoresistance and metastasis of pancreatic cancer cells. DOI 10.1038/oncsis.2015.45↗
- Paper Novel immunocompetent murine models representing advanced local and metastatic pancreatic cancer. DOI 10.1016/j.jss.2011.10.025↗
- Paper Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine t… DOI 10.1038/cgt.2013.9↗
- Dennis K. Watson · 3 shared papers, 2012–2016 · strength 0.14
- Paper The CaSm (LSm1) oncogene promotes transformation, chemoresistance and metastasis of pancreatic cancer cells. DOI 10.1038/oncsis.2015.45↗
- Paper Novel immunocompetent murine models representing advanced local and metastatic pancreatic cancer. DOI 10.1016/j.jss.2011.10.025↗
- Paper Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine t… DOI 10.1038/cgt.2013.9↗
- Chrystal M Paulos · 1 shared paper, 2017 · strength 0.06
- Shikhar Mehrotra · 1 shared paper, 2017 · strength 0.06
- Mark P. Rubinstein · 1 shared paper, 2017 · strength 0.06
- Carolyn D. Britten · 1 shared paper, 2017 · strength 0.06
- Nestor F. Esnaola · 1 shared paper, 2014 · strength 0.04
- David T. Marshall · 1 shared paper, 2014 · strength 0.04
- Alberto J. Montero · 1 shared paper, 2014 · strength 0.04
- Paul E. O’Brien · 1 shared paper, 2014 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.